Publications & Press Releases

Scientific Publications

2022

• Scarneo, Scott, Philip Hughes, Robert Freeze, Kelly Yang, Juliane Totzke, and Timothy Haystead. "Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis." ACS Chemical Biology (2022).

2021

2020

• Scarneo, S. A., Hughes, P. F., Yang, K. W., Carlson, D. A., Gurbani, D., Westover, K. D., & Haystead, T. A. (2020). A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. Journal of Biological Chemistry, 295(6), 1565-1574.
• Totzke, J., Scarneo, S. A., Yang, K. W., & Haystead, T. A. (2020). TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biology, 10(9), 200099.
• Scarneo, S. A., Yang, K. W., Roques, J. R., Dai, A., Eibschutz, L. S., Hughes, P., & Haystead, T. A. (2020). TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. Oncotarget, 11(21), 1961.

2019

• Scarneo, S. A., Eibschutz, L. S., Bendele, P. J., Yang, K. W., Totzke, J., Hughes, P., ... & Haystead, T. A. (2019). Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis research & therapy, 21(1), 1-10.

2018

• Scarneo, S. A., Mansourati, A., Eibschutz, L. S., Totzke, J., Roques, J. R., Loiselle, D., ... & Haystead, T. A. (2018). Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific reports, 8(1), 1-11.

2017

• Totzke, J., Gurbani, D., Raphemot, R., Hughes, P. F., Bodoor, K., Carlson, D. A., ... & Derbyshire, E. R. (2017). Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-α inhibition for cancer and autoimmune disease. Cell chemical biology, 24(8), 1029-1039.